Arcus Biosciences stock edges higher to $29.97 after new clinical partnership announcement

Arcus Biosciences stock edges higher to $29.97 after new clinical partnership announcement
Arcus Biosciences rises 1.66% today

Arcus Biosciences announced a clinical supply agreement with AVEO Oncology. The agreement will evaluate casdatifan, Arcus Biosciences' investigational HIF-2α inhibitor, in combination with a VEGFR tyrosine kinase inhibitor.

Highlights

  • RCUS shows sustained bullish momentum across all timeframes, trading near the top of its range following a 9.5% weekly advance.
  • Key technical support is clustered at 29.24–27.52, with resistance at 31.74; a breakout above could target 33.00.
  • Technical indicators remain bullish but suggest the uptrend lacks strong conviction, with the probability of continued gains exceeding 80%.

The combination will be assessed in a new cohort of the ARC-20 platform study for patients with advanced disease. Further information is available through the company's official channel.

Bullish momentum sustained as moving averages align above support zones

RCUS is trading at $29.97, currently above the MA-20 ($29.24), MA-50 ($26.21), and MA-200 ($22.73). This alignment signals sustained short-, medium-, and long-term bullish momentum, while the Ichimoku Kijun at $27.52 now acts as immediate support. Near-term support is found at $29.24 (MA-20), with key support at $26.21 (MA-50). Immediate resistance is near $31.74, the 52-week high, followed by $29.97, where price is pressing at range highs.

Upward price recovery persists as momentum signals show buyer dominance

Momentum signals remain bullish on D1, with MACD showing a strong buy and ADX at a low 14.91, suggesting the uptrend lacks conviction but is persistent. RSI on D1 sits moderately high at 58.05, with Stoch RSI and CCI showing neutral to mild overbought conditions, especially as BBP at 1.07 highlights ongoing buyer dominance intraday. AO is also supportive of continued upside. RCUS has risen $2.60 (9.5%) over the past week, trading up from $27.37, and is ending the week at the very top of the range. Weekly volatility stands at 15.15%. This strong advance indicates a sharp recovery from earlier lows, with buyers maintaining control and price action consolidating at the highs.

Further gains likely as buy indicators cluster and resistance nears

Looking ahead, next week’s realistic trading range is anticipated between $28.00 and $33.00, as the original forecast high of $36.58 would exceed the 20% normalization band for a $29.97 asset. This range remains well above the 52-week low of $8.84 and is approaching—but not exceeding—the 52-week high at $31.74 for context. The probability of a further price increase is very high (more than 80%), given all W1 indicators (RSI, ADX, MACD, and MA-50) show Buy signals, so the chance of a decline is very low (less than 20%). The baseline scenario sees RCUS consolidating just below the 52-week high within a tight corridor. A bullish scenario would feature a clear breakout above $31.74, encouraging momentum toward the upper $33.00 area. A bearish scenario would only emerge if the price breaks below the $29.24–$27.52 support cluster, risking a pullback toward the $26.21 region.

Previously it was reported that Arcus Biosciences maintained a broadly bullish trend, with analysts highlighting the potential for further upside despite short-term volatility. As market conditions evolve, traders should watch for emerging shifts in momentum that could present new entry points in the coming sessions.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.